Quick Answer
Longevity Health Holdings, Inc. reported Research And Development Expense of $788.9 thousand for the year ending 2025.
- Longevity Health Holdings, Inc. showed a decrease of -25.2% in Research And Development Expense from 2024 to 2025.
- This data is from Longevity Health Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $570.9 thousand | Q1 2023: $740.3 thousand | Q2 2023: $823.7 thousand | Q3 2023: $1.59 million | Q1 2024: $429.4 thousand | Q2 2024: $104.1 thousand | Q3 2024: $331.8 thousand | Q1 2025: $196.9 thousand | Q2 2025: $259.9 thousand | Q3 2025: $228.0 thousand.
- Over the full 4 years of available data (2022 to 2025), Longevity Health Holdings, Inc.'s Research And Development Expense has declined by 64.1%.
- Historical annual values: Fiscal year 2025: $788.9 thousand | Fiscal year 2024: $1.05 million | Fiscal year 2023: $2.50 million | Fiscal year 2022: $2.20 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: